




Driven by Excellence.  
Guided by Science.

In a 2019 survey of customers developing biologics with Selexis' SUREtechnology™ Platform, our partners responded with:



## OVERALL SATISFACTION


- ✓ Are satisfied with Selexis and the SUREtechnology Platform
- ✓ Would use Selexis technology again and recommend Selexis to an associate



## SCIENTIFIC SUPPORT

- ✓ Are satisfied with the level of scientific expertise and technical support provided by Selexis and that the Selexis team understands their product development challenges
- ✓ Feel the Selexis scientific team is responsive to all technical and development questions

**91%** agree that their business relationship with Selexis is built on **trust and respect**



## LONG-TERM PARTNER

- ✓ Selexis puts great effort into problem-solving
- ✓ Partners feel they can rely on Selexis as a long-term partner that searches for solutions based on the spirit of collaboration and scientific excellence
- ✓ Value Selexis' ongoing investment in science and technology

## SELEXIS SURE CELL LINE DEVELOPMENT™

Proprietary technology platform and comprehensive services for fast and reliable cell line development:

- Highly adaptable non-viral vectors with no carrying-capacity limitation
- No gene amplification required
- Novel high-throughput approach to address product-specific expression bottlenecks
- Proven track record in the expression of MAbs, enzymes, Fc-fusions, GPCRs, ion channels and more
- Documentation ready for IND filing including detailed vector information and host cell line pedigree
- Precise mapping of the transgene integration site(s)
- World-class science, project management
- Highly efficient tech transfer to CMOs

## HIGH PERFORMANCE, STABLE RESEARCH CELL BANKS

- No viruses
- Strong expression vectors
- High performance host cell
- Chemically defined, serum-free medium
- Robust and easily transferable feed strategy






## ENGAGEMENT

- ✓ Are satisfied with Selexis as a development partner and feel that Selexis is an easy company to deal with
- ✓ Agree Selexis is a flexible, proactive partner and are satisfied with the way Selexis conducts business
- ✓ Feel the Selexis team is responsive to their needs

**91%** feel Selexis is **committed** to helping them meet their development needs



## VALUE-ADDED PARTNER

- ✓ Think of Selexis first when thinking of quality partners
- ✓ Feel their relationship with Selexis adds value to their company and work
- ✓ Agree Selexis fosters and encourages open and honest dialogue with its collaborators

Connect with the leaders in cell line development. From difficult-to-express to novel proteins, Selexis is your partner of choice: [www.selexis.com](http://www.selexis.com)

**HEADQUARTERS**  
 Selexis SA  
 Chemin des Aulx, 14  
 1228 Plan-les-Ouates SWITZERLAND  
 T +41 (0)22 308 93 60

Driven by Excellence.  
 Guided by Science.  
 Valued by Partners.

## WHAT OUR PARTNERS ARE SAYING



*The productivity of the cell lines that Selexis made for us was impressive...*

*It was a pleasure working with Selexis on our project.*

*Communication with Selexis is always smooth, professional and time-efficient. The technology is innovative and the output very impressive. Selexis is always ready to go the extra mile...*

*We obtained cell lines with consistently very high titers for our non-traditional bispecific antibodies.*

*Our program manager was very responsive and attentive. We genuinely enjoyed collaborating with her and the rest of her team.*

*Both our BD representative and our PM are very responsive and open — anytime we have questions or issues, they are resolved quickly.*

*Our experiences and interactions with the Selexis teams have all been very positive. I appreciate the speed and flexibility by the project managers to accommodate any inquiry/request I've had over the past several years.*

*Very respectful, trustworthy relationship. I know if I have quick turnaround needed, the Selexis team will do its best to meet the timeline.*

*I was pleased to learn that Selexis invests in new technologies to improve its platform instead of relying on an established platform approach.*



A JSR Life Sciences Company